Congenital heart disease is the most common birth defect in children, caused by abnormal development of the heart and great vessels during the fetal period. The global incidence is 8‰-12‰.It is divided into simple CHD (ventricular septal defect, atrial septal defect, patent ductus arteriosus, etc.) and complex critical CHD (tetralogy of Fallot, transposition of the great arteries, hypoplastic left heart syndrome, etc.). Without timely treatment, it will lead to pulmonary hypertension, heart failure, growth retardation and even death, and critical complex CHD often requires intervention in the neonatal period.
: China has the largest annual CHD surgery volume in the world (over 140,000 cases). The success rate of simple CHD radical surgery exceeds 99%, and the success rate of complex CHD surgery exceeds 95%. The success rate of neonatal complex CHD surgery in top centers (e.g. National Children's Medical Center) is over 97%, on par with top European and American centers.
: China is a global leader in ultrasound-guided radiation-free interventional occlusion, robot-assisted pediatric cardiac surgery, and cardiac surgery for ultra-low birth weight premature infants (under 1kg), which is strictly limited in many European and American centers.
: A complete chain from prenatal diagnosis, intrauterine intervention, neonatal treatment, postoperative rehabilitation to long-term follow-up, with a prenatal diagnosis accuracy rate of over 95%, enabling immediate surgery after birth for critical cases.
: The treatment cost is only 1/5-1/3 of that in the US and Europe with the same technical level, and there is no long waiting time. Critical surgery can be arranged within 24-72 hours, while the waiting period in Europe and America is often weeks to months.
